Free Trial
NASDAQ:MRKR

Marker Therapeutics (MRKR) Stock Price, News & Analysis

Marker Therapeutics logo
$3.38 -0.04 (-1.17%)
(As of 12/24/2024 05:10 PM ET)

About Marker Therapeutics Stock (NASDAQ:MRKR)

Key Stats

Today's Range
$3.30
$3.75
50-Day Range
$2.93
$4.86
52-Week Range
$2.44
$6.16
Volume
82,296 shs
Average Volume
31,291 shs
Market Capitalization
$30.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Buy

Company Overview

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Marker Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
89th Percentile Overall Score

MRKR MarketRank™: 

Marker Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 119th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Marker Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Marker Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($1.05) to ($2.19) per share.

  • Price to Book Value per Share Ratio

    Marker Therapeutics has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.78% of the float of Marker Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Marker Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Marker Therapeutics has recently decreased by 12.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Marker Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Marker Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.78% of the float of Marker Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Marker Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Marker Therapeutics has recently decreased by 12.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Marker Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Marker Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Marker Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,773,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    17.35% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.39% of the stock of Marker Therapeutics is held by institutions.

  • Read more about Marker Therapeutics' insider trading history.
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Marker Therapeutics sells 5.03M shares at $3.20 in private placement
See More Headlines

MRKR Stock Analysis - Frequently Asked Questions

Marker Therapeutics' stock was trading at $5.50 at the beginning of 2024. Since then, MRKR shares have decreased by 38.5% and is now trading at $3.38.
View the best growth stocks for 2024 here
.

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative net margin of 179.74% and a negative trailing twelve-month return on equity of 89.63%.

Top institutional investors of Marker Therapeutics include Invst LLC (0.22%).
View institutional ownership trends
.

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/10/2021
Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
60
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$19.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+462.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,240,000.00
Net Margins
-179.74%
Pretax Margin
-178.50%

Debt

Sales & Book Value

Annual Sales
$3.31 million
Book Value
$1.58 per share

Miscellaneous

Free Float
7,376,000
Market Cap
$30.16 million
Optionable
Not Optionable
Beta
1.45

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:MRKR) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners